Congress designates September for sickle cell awareness, highlights gene therapy breakthroughs
S.Res. 416 — A resolution expressing support for the designation of September 2025 as "Sickle Cell Disease Awareness Month" in order to educate communities across the United States about sickle cell disease and the need for research, early detection methods, effective treatments, and preventative care programs with respect to complications from sickle cell disease and conditions related to sickle cell disease. · Filed by Tim Scott (R-SC) · 7 cosponsors · Introduced Sep 19, 2025 · Passed chamber
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This is a Senate resolution designating September 2025 as 'Sickle Cell Disease Awareness Month' to educate the public about sickle cell disease, a serious inherited blood disorder affecting approximately 100,000 Americans—disproportionately Black and Hispanic populations. The resolution encourages communities to hold events and programs raising awareness about the disease, early detection, treatments, and preventative care, and notes recent FDA approvals of gene therapies that can cure the condition.
Why we flagged it
This is a straightforward commemorative resolution designating a month for disease awareness. It contains no legislative mechanism, appropriation, or regulatory change—only a statement of support and encouragement for public education and community events.
What the text implies
- The resolution's emphasis on recent FDA-approved gene therapies and CMS's 'innovative cell and gene therapy access model' may indirectly signal support for expanded Medicaid coverage and reimbursement of expensive gene therapies, which could influence future policy discussions around drug pricing and access.
- By highlighting disparate disease burden (1 in 365 Black infants vs. 1 in 16,300 Hispanic infants), the resolution frames sickle cell disease as a racial health equity issue, which may strengthen future arguments for targeted research funding and health equity initiatives.
Who stands to gain
gene therapy manufacturers; pharmaceutical companies with approved sickle cell treatments